DR8 DataRelease

SDY261: MicroRNA Regulation of Human Protease Genes
Status: New
Description: the human protease genes required for influenza virus replication were determined and validated using RNA interference approaches. The genes validated as critical for influenza virus replication were ADAMTS7, CPE, DPP3, MST1, and PRSS12, and pathway analysis showed these genes were in global host cell pathways governing inflammation (NF-kB), cAMP/calcium signaling (CRE/CREB), and apoptosis.
Program/Contract:
ProgramContract
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3KPHZF88E
Subjects: 1
Study PI, contact:
NameOrganizationSite
Ralph Tripp Department of Infectious Diseases, University of Georgia Department of Infectious Diseases, University of Georgia
Publications:
MicroRNA regulation of human protease genes essential for influenza virus replication.. PLoS One. - 2012. doi: 10.1371/journal.pone.0037169. Epub 2012 May 14. [Pubmed: 22606348]
Resources:
Emory University Influenza Pathogenesis & Immunology Research Center www.medicine.emory.edu/ipirc]
Assays:
Assay TypeNumber of Exp. Samples
Liquid Chromatography 8
Other 28
Q-PCR 13
TCID50 23
Transcription profiling assay 4
Clinical Assessments:None
SDY262: SWHP03 A novel pig model of Helicobacter pylori infection demonstrating Th1 and cytotoxic T cell responses
Status: New
Description: Pigs were divided into 4 groups of uninfected (n=9), infected with H. pylori strain J99 (n=9), strain SS1 (n=8) and SW-SS1 (n=9). Following a 12-hour fasting period, bacterial challenge was performed by orogastric gavage with 1x1010 CFU H. pylori live organisms (strains J99, SS1 or SW-SS1) resuspended in sterile brucella broth administered on days 0 and 2 of the study. As a control, the uninfected group received sterile brucella broth without any bacteria. A delay in gastric emptying was ensured by oral administration of brucella broth supplemented with fetal bovine serum (FBS) prior to the bacterial or mock challenges. To suppress gastric acidity and to increase the efficiency of H. pylori colonization, all pigs received Famotidine (1mg/kg) intramuscularly 90 minutes prior to each bacterial and control inoculation and 5% urea was added to drinking water for 4 days post-infection to provide sufficient substrate for H. pylori urease and to increase gastric pH. Pigs were monitored and scored for clinical signs of disease daily. Peripheral blood was collected from the vena cava weekly to study systemic immune responses by flow cytometry. Pigs were euthanized between day 51 and 60 post-infection to assess gastric colonization with H. pylori, to study lesions and local immune responses in the gastric mucosa and lymph node (GLN). Tissue was collected from 3 major regions of the stomach: fundus gland (F), pyloric gland (P), cardiac gland (C) and further subdivided in 2 sections (F-A, F-B, P-A, P-B, C-A, C-B) for specific applications. Furthermore, Spleen and GLN were collected for further analysis.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II Virginia Bioinformatics Institute Modeling Immunity for Biodefense Contract
DOI: 10.21430/M3BAR04LX3
Subjects: 35
Study PI, contact:
NameOrganizationSite
Josep Bassaganya-Riera NIMML VBI
Raquel Hontecillas NIMML VBI
Publications:
Helicobacter pylori infection in a pig model is dominated by Th1 and cytotoxic CD8+ T cell responses.. Infect Immun. Oct 2013. doi: 10.1128/IAI.00660-13. Epub 2013 Jul 29. [Pubmed: 23897614]
Resources:
MIEP http://www.modelingimmunity.org/]
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 140
Flow Cytometry 2785
Microscopy 156
Other 168
Q-PCR 234
Clinical Assessments:None
SDY264: Strategies to alleviate original antigenic sin
Status: New
Description: They found that dendritic cell-activating adjuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalenebased oil-in-water nanoemulsion (NE)], upon administration during the second viral exposure, completely protected mice from a lethal challenge and enhanced neutralizing-Ab titers against the second virus.
Program/Contract:
ProgramContract
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3EQ20FG3W
Subjects: 21
Study PI, contact:
NameOrganizationSite
Joshy Jacob Emory Vaccine Center, Emory University Emory Vaccine Center, Emory University
Publications:
Strategies to alleviate original antigenic sin responses to influenza viruses.. Proc Natl Acad Sci U S A. Aug 2012. doi: 10.1073/pnas.0912458109. Epub 2012 Aug 6. [Pubmed: 22869731]
Resources:
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 8
Other 72
Clinical Assessments:None
SDY269: Systems Biology of 2008 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine)
Status: New
Description: Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2008-2009 influenza season.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3CDX6TL4I
Subjects: 63
Study PI, contact:
NameOrganizationSite
Bali Pulendran Emory University Emory Vaccine Center,
Publications:
Systems biology of vaccination for seasonal influenza in humans.. Nat Immunol. Jul 2011. doi: 10.1038/ni.2067. [Pubmed: 21743478]
Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.. Immunity. Dec 2015. doi: 10.1016/j.immuni.2015.11.012. [Pubmed: 26682988]
Resources:
Emory Vaccine Center http://www.vaccines.emory.edu/]
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29615]
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29617]
Assays:
Assay TypeNumber of Exp. Samples
ELISPOT 336
Flow Cytometry 59
Hemagglutination Inhibition 336
Luminex xMAP 168
Q-PCR 75
Transcription profiling by array 263
Clinical Assessments:None
SDY270: Systems Biology of 2009 Influenza Vaccination in Humans (See companion studies SDY61 2007 / SDY269 2008 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine)
Status: New
Description: Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2009-2010 influenza season.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3H9N1SFLO
Subjects: 30
Study PI, contact:
NameOrganizationSite
Bali Pulendran Emory University Emory Vaccine Center,
Publications:
Systems biology of vaccination for seasonal influenza in humans.. Nat Immunol. Jul 2011. doi: 10.1038/ni.2067. [Pubmed: 21743478]
Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.. Immunity. Dec 2015. doi: 10.1016/j.immuni.2015.11.012. [Pubmed: 26682988]
Resources:
Emory Vaccine Center http://www.vaccines.emory.edu/]
Assays:
Assay TypeNumber of Exp. Samples
Hemagglutination Inhibition 168
Q-PCR 90
Transcription profiling by array 83
Clinical Assessments:None
SDY271: Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine (See companion studies SDY61 2007 / SDY269 2008 / SDY270 2009)
Status: New
Description: To demonstrate that the gene signatures identified in this study can generate new hypotheses, we selected one gene in the predictive signature, calcium/calmodulin-dependent protein kinase IV (CaMKIV), for functional validation experiments. The CamkIV gene is involved in several processes of the immune system, such as T cell development,inflammatory response and hematopoietic stem cell maintenance. However, nothing is known about the possible role of CaMKIV in B cell responses. The fold-change in expression of the CaMKIV gene on day 3 post-TIV vaccination is negatively correlated with the antibody response on day 28 post-vaccination in two independent trials. Additionally, fold-change expression of CaMKIV is negatively correlated with the expansion of IgG-secreting plasmablasts at day 7, suggesting a possible role for this gene in the regulation of antibody responses to influenza vaccination.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M321YJ41HJ
Subjects: 36
Study PI, contact:
NameOrganizationSite
Bali Pulendran Emory University Emory Vaccine Center,
Publications:
Systems biology of vaccination for seasonal influenza in humans.. Nat Immunol. Jul 2011. doi: 10.1038/ni.2067. [Pubmed: 21743478]
Resources:
Emory Vaccine Center http://www.vaccines.emory.edu/]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 100
Immunoblot 26
Q-PCR 4
Clinical Assessments:None
SDY1: Efficacy and Safety Evaluation of Allergen Immunotherapy Co-Administered with Omalizumab (an anti-IgE Monoclonal Antibody)
Status: Updated
Description:

Allergic rhinitis affects 20 to 40 million Americans annually. Allergy symptoms, which can range from mild to seriously debilitating, may affect quality of life. Left untreated, allergic rhinitis can exacerbate or trigger more serious conditions, such as asthma and sinus inflammation.

Individuals with allergies react to harmless particles such as dust or pollen. Proteins in the blood called IgE antibodies treat the harmless particles as invaders and trigger an immune system response. The immune response results in harmful inflammation of healthy tissues. In ragweed allergy, inflammation occurs in the airways and causes familiar allergy symptoms like sneezing, coughing, and general discomfort.

Omalizumab is an investigational drug that has been shown to block the effects of IgE antibodies. The blocking effect of omalizumab is temporary, but giving the drug to people before their regular allergy shots may make the shots more effective.

Participants in this study will be randomly assigned to receive injections of omalizumab or a placebo before an accelerated course of allergy shots (given over 12 weeks). The participants will return for follow-up for up to one year, and they may have as many as 27 study visits.

Program/Contract:
ProgramContract
ITN: Collaborative Network for Clinical Research on Immune Tolerance Network Immune Tolerance Network - Casale
DOI: 10.21430/M38Y09R3R9
Subjects: 159
Study PI, contact:
NameOrganizationSite
Thomas Casale Creighton University School of Medicine Creighton University
Publications:
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.. J Allergy Clin Immunol. Jan 2006. doi: b 2005 Dec 2. [Pubmed: 16387596]
Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding.. J Allergy Clin Immunol. Sep 2007. doi: b 2007 Jul 12. [Pubmed: 17631952]
Resources:
Clinicaltrials.gov http://clinicaltrials.gov/ct2/show/NCT00078195]
ImmuneTolerance.org http://www.immunetolerance.org/studies/efficacy-and-safety-evaluation-allergen-immunotherapy-co-administered-with-omalizumab-anti-i]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 4376
Flow Cytometry 14462
Clinical Assessments:
15 mins post injection allergy skin reaction measurement
24 hrs post injection allergy skin reaction measurement
Allergen History
Allergy Symptom History
Animal Exposure History
Food Allergy History
Immunotherapy History
Other Allergy History
Participant Diary Card Record
Pre-injection Measurement for Rush immunotherapy(Histamine)
Pre-injection Measurement for Rush immunotherapy(Ragweed)
Vital Signs
SDY61: Systems Biology of 2007 Influenza Vaccination in Humans (See companion studies SDY269 2008 / SDY270 2009 / SDY271 Role for CaMKIV in the Regulation of Antibody Responses to Influenza Vaccine)
Status: Updated
Description: Using a systems biology approach to study innate and adaptive responses to influenza vaccination in humans during the 2007-2008 influenza season.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Biological Analysis of Innate and Adaptive Responses to Vaccination
NIAID Centers of Excellence for Influenza Research and Surveillance (CEIRS) Influenza Pathogenesis & Immunology Research Center (IPIRC)
DOI: 10.21430/M3FH0SA2W0
Subjects: 12
Study PI, contact:
NameOrganizationSite
Bali Pulendran Emory Vaccine Center, Emory University Emory Vaccine Center
Publications:
Systems biology of vaccination for seasonal influenza in humans.. Nat Immunol. Jul 2011. doi: 10.1038/ni.2067. [Pubmed: 21743478]
Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures.. Immunity. Dec 2015. doi: 10.1016/j.immuni.2015.11.012. [Pubmed: 26682988]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE29614]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 4
Hemagglutination Inhibition 54
Q-PCR 27
Transcription profiling by array 27
Clinical Assessments:None
SDY167: VRC304 - A Phase I Study of the Safety and Immunogenicity of a Recombinant DNA Plasmid Vaccine (VRC-AVIDNA036-00-VP) Encoding for the Influenza Virus H5 Hemagglutinin Protein in Healthy Adults
Status: Updated
Description: The primary objective was to evaluate the safety and tolerability of an investigational vaccine VRC-AVIDNA036-00-VP in humans at doses 1 mg and 4 mg administered intramuscularly using a needle-free injection system. The secondary objectives included evaluation of whether VRC-AVIDNA036-00-VP (at doses 1 mg and 4 mg) induced antibodies as assessed by an HAI assay at Day 0 and Week 12. Exploratory analyses included evaluation of the immunogenicity of VRC-AVIDNA036-00-VP at doses 1 mg and 4 mg using intracellular cytokine staining, ELISpot, neutralizing antibody assay, HAI assay to H1 or H3HA or other immunological assays at time intervals between Day 0 and Week 42.
Program/Contract:
ProgramContract
NIAID Vaccine Research Center (VRC) NIAID Vaccine Research Center (VRC)
DOI: 10.21430/M3SGHW16WZ
Subjects: 45
Study PI, contact:
NameOrganizationSite
Julie Ledgerwood Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID)
Publications:
Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans.. Clin Vaccine Immunol. Nov 2012. doi: 10.1128/CVI.05663-11. Epub 2012 Sep 5. [Pubmed: 22956656]
Resources:
ClinicalTrials.gov http://clinicaltrials.gov/ct2/show/NCT00408109]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 430
ELISPOT 300
Flow Cytometry 874
Hemagglutination Inhibition 44
Virus Neutralization 88
Clinical Assessments:None
SDY180: Systems scale interactive exploration reveals quantitative and qualitative differences in response to 2009-2010 Fluzone influenza vaccine and pneumococcal vaccine
Status: Updated
Description: Systems immunology approaches were employed to investigate innate and adaptive immune responses to influenza and pneumococcal vaccines. These two non-live vaccines show different magnitudes of transcriptional responses at different time points af- ter vaccination. Software solutions were developed to explore correlates of vaccine efficacy measured as antibody titers at day 28. These enabled a further dissection of transcriptional responses. Thus, the innate response, measured within hours in the peripheral blood, was dominated by an interferon transcriptional signature after influenza vaccination and by an inflammation signature after pneumo- coccal vaccination. Day 7 plasmablast responses induced by both vaccines was more pronounced after pneumococcal vaccination. Together, these results suggest that comparing global immune responses elicited by different vaccines will be critical to our understanding of the immune mechanisms underpinning successful vaccination.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Systems Analysis Vaccine Responses in Healthy and Hyporesponsive Humans
DOI: 10.21430/M3I44H8R17
Subjects: 46
Study PI, contact:
NameOrganizationSite
A. Karolina Palucka Baylor Reasearch Institute Baylor Reasearch Institute
Publications:
Systems scale interactive exploration reveals quantitative and qualitative differences in response to influenza and pneumococcal vaccines.. Immunity. Apr 2013. doi: 10.1016/j.immuni.2012.12.008. [Pubmed: 23601689]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE30101]
Assays:
Assay TypeNumber of Exp. Samples
DNA microarray 542
Flow Cytometry 2208
Hemagglutination Inhibition 66
Luminex xMAP 229
Nanostring 18
Transcription profiling by array 161
Virus Neutralization 89
Clinical Assessments:None
SDY212: Apoptosis and other immune biomarkers predict influenza vaccine (TIV 2008) responsiveness
Status: Updated
Description: Despite the importance of the immune system in many diseases, there are currently no objective benchmarks of immunological health. In an effort to indentify benchmarks of immunological health, influenza vaccination was used in 30 young (20-30 years) and 59 older subjects (60 to 89 years) as models for strong and weak immune responses, respectively. Serological responses to influenza strains as well as a wide variety of other parameters, including gene expression, antibodies to hemagglutinin peptides, serum cytokines, cell subset phenotypes and in vitro cytokine stimulation were measured. Using machine learning, nine variables predicting antibody response with 84% accuracy were identified. Two of these variables are involved in apoptosis, which positively associated with the response to vaccination and was confirmed to be a contributor to vaccine responsiveness in mice. The identification of these biomarkers provides new insights into what immune features may be most important for immune health.
Program/Contract:
ProgramContract
Human Immunology Project Consortium 1 (HIPC1) Vaccination and infection: indicators of immunological health and responsiveness
DOI: 10.21430/M37NGTHMDS
Subjects: 91
Study PI, contact:
NameOrganizationSite
Mark M. Davis Stanford University Stanford-LPCH Vaccine Program
Publications:
Apoptosis and other immune biomarkers predict influenza vaccine responsiveness.. Mol Syst Biol. Apr 2013. doi: 10.1038/msb.2013.15. [Pubmed: 23591775]
Effects of aging, cytomegalovirus infection, and EBV infection on human B cell repertoires.. J Immunol. Jan 2014. doi: 10.4049/jimmunol.1301384. Epub 2013 Dec 11. [Pubmed: 24337376]
Defective Signaling in the JAK-STAT Pathway Tracks with Chronic Inflammation and Cardiovascular Risk in Aging Humans.. Cell Syst. Oct 2016. doi: 10.1016/j.cels.2016.09.009. Epub 2016 Oct 13. [Pubmed: 27746093]
Resources:
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE41080]
Assays:
Assay TypeNumber of Exp. Samples
Flow Cytometry 1086
Hemagglutination Inhibition 534
Luminex xMAP 91
Protein microarray 91
Transcription profiling by array 91
Clinical Assessments:None
SDY224: Immune Responses to Seasonal TIV 2010-2011 Influenza Vaccination in Humans (see companion study SDY396,SDY564)
Status: Updated
Description: High-frequency sampling combined with systems biology analysis of human peripheral blood cells following influenza vaccination was used to investigate T cell and B cell responses. Functional principal component analysis was used to examine time varying B cell vaccine response highlighting a single subject-specific mathematical pattern explaining ninety percent of the transcriptome variation. In addtition, daily sampling and monitoring of the proliferation marker Ki-67, revealed influenza-specific CD4 T cells do respond to vaccination.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense II University of Rochester Center for Biodefense Immune Modeling II
DOI: 10.21430/M37KMO7JLW
Subjects: 14
Study PI, contact:
NameOrganizationSite
Hulin Wu University of Rochester Medical Center University of Rochester Medical Center
Martin Zand University of Rochester Medical Center University of Rochester Medical Center
Publications:
Ki-67 expression reveals strong, transient influenza specific CD4 T cell responses after adult vaccination.. Vaccine. Jun 2012. doi: 10.1016/j.vaccine.2012.04.059. Epub 2012 Apr 30. [Pubmed: 22554464]
High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature.. Sci Rep. - 2013. doi: 10.1038/srep02327. [Pubmed: 23900141]
Resources:
University of Rochester Center for Biodefense Immune Modeling https://cbim.urmc.rochester.edu/]
Gene Expression Omnibus (GEO) http://www.ncbi.nlm.nih.gov/sra?term=SRX259436]
Effect of influenza vaccination on PBMC and B cell gene expression profiles in healthy humans http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE45764]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 423
ELISPOT 120
Flow Cytometry 560
Hemagglutination Inhibition 543
Q-PCR 1548
Sequencing 110
Clinical Assessments:None
SDY241: Simulation and Prediction of the Adaptive Immune Response and Quantification of Early and Adaptive Immune Response Kinetics to Influenza A Virus Infection
Status: Updated
Description: Seasonal and pandemic influenza A virus (IAV) continues to be a public health threat. Modeling approaches were used combined with experimental data to investigate innate and adaptive immune responses to IAV infection. Mathematical models developed describe the dynamic interactions between influenza virus, target cells, cytotoxic lymphocytes, and virus-specific IgG and IgM. A two-compartment model developed quantifies the effects of viral replication and adaptive immunity.
Program/Contract:
ProgramContract
Modeling Immunity for Biodefense University of Rochester Center for Biodefense Immune Modeling
DOI: 10.21430/M3ERWHDJEO
Subjects: 494
Study PI, contact:
NameOrganizationSite
David Topham University of Rochester University of Rochester
Hulin Wu University of Rochester University of Rochester
Publications:
Simulation and prediction of the adaptive immune response to influenza A virus infection.. J Virol. Jul 2009. doi: 10.1128/JVI.00098-09. Epub 2009 May 13. [Pubmed: 19439465]
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus.. J Virol. Jul 2010. doi: 10.1128/JVI.00266-10. Epub 2010 Apr 21. [Pubmed: 20410284]
Modeling of influenza-specific CD8+ T cells during the primary response indicates that the spleen is a major source of effectors.. J Immunol. Nov 2011. doi: 10.4049/jimmunol.1101443. Epub 2011 Sep 23. [Pubmed: 21948988]
Functionally Distinct Subpopulations of CpG-Activated Memory B Cells.. Sci Rep. - 2012. doi: 10.1038/srep00345. Epub 2012 Mar 30. [Pubmed: 22468229]
Ki-67 expression reveals strong, transient influenza specific CD4 T cell responses after adult vaccination.. Vaccine. Jun 2012. doi: 10.1016/j.vaccine.2012.04.059. Epub 2012 Apr 30. [Pubmed: 22554464]
High-resolution temporal response patterns to influenza vaccine reveal a distinct human plasma cell gene signature.. Sci Rep. - 2013. doi: 10.1038/srep02327. [Pubmed: 23900141]
Resources:
University of Rochester Center for Biodefense Immune Modeling https://cbim.urmc.rochester.edu/]
Immune Epitope Database (IEDB) http://www.iedb.org/reference/1024464]
Assays:
Assay TypeNumber of Exp. Samples
ELISA 1866
ELISPOT 485
Flow Cytometry 5090
Clinical Assessments:None
Back to top